Form 4: Madrigal Pharma Director Bate Exercises Options, Sells Shares

Director Kenneth Bate exercised stock options and sold shares of Madrigal Pharmaceuticals on August 15, 2025.

Summary

• Director Kenneth Bate exercised options to purchase 10,000 shares of Madrigal Pharmaceuticals (MDGL) common stock at a price of $16.46 on August 15, 2025.
• Bate sold 2,317 shares at a weighted average price of $363.4072, 2,516 shares at a weighted average price of $364.2399, 2,567 shares at a weighted average price of $365.3264, 600 shares at a weighted average price of $366.1383, 1,104 shares at a weighted average price of $367.6311 and 896 shares at a weighted average price of $368.5557 on the same day.
• Following these transactions, Bate directly owns 2,627 shares of Madrigal Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: Neutral. The filing represents routine transactions (option exercise and share sales) by a company director.

Positives

• The exercise of stock options indicates confidence in the company's future prospects, as the director chose to convert the options into shares.

Negatives

• The sale of shares by a director could be interpreted negatively by the market, although it may be for personal financial reasons.

Future Outlook

There are no explicit forward-looking statements in this filing.

Industry Context

This filing reflects insider transactions, which are common in the pharmaceutical industry. Investors often monitor these transactions for signals about management's view of the company's prospects.

Comparison to Industry Standards

• Stock option exercises and sales are a standard part of executive compensation in publicly traded companies, including pharmaceutical firms.
• Comparable companies such as Viking Therapeutics (VKTX) and Intercept Pharmaceuticals (ICPT) also see regular Form 4 filings related to insider transactions.

Stakeholder Impact

• Shareholders: May react to the director's share sales, although the impact is likely to be minimal given the relatively small number of shares involved.
• Employees: No direct impact.

Key Dates

Recommendation

The filing represents routine transactions (option exercise and share sales) by a company director. There is no fundamental reason to change the recommendation for the stock.

Keywords

Madrigal Pharmaceuticals, MDGL, Kenneth Bate, stock options, share sale, director, Form 4, SEC filing